ABLYNX RECEIVES ?1.1 MILLION GRANT TO FURTHER DEVELOP NEW ROUTES OF
ADMINISTRATION FOR NANOBODIES®
(Thomson Reuters ONE) - GHENT, Belgium, 23 November 2009 - Ablynx [Euronext Brussels: ABLX],announced today that it has been awarded a grant worth ?1.1 millionby the Flemish agency for Innovation by Science and Technology (IWT).The grant allows Ablynx to accelerate its development of alternativeroutes of administration for therapeutic Nanobodies, and build on thesuccesses that have been achieved so far in this area. In December2008, Ablynx concluded its first feasibility study of pulmonarydelivery and demonstrated in vivo that anti-viral Nanobodies protectagainst viral infection and eliminate active virus when delivered viaan intra-pulmonary route. Ablynx has also demonstrated that Nanobodyadministration via the lungs resulted in up to 10 times longersystemic exposure compared with intravenous administration.Ablynx will use the grant to accelerate the development of pulmonaryand oral delivery technologies for its Nanobodies. The Company willcontinue to explore several other potential routes including topicaland ocular administration.Edwin Moses, CEO and Chairman of Ablynx, said: "We are very pleasedwith IWT's continued support of Ablynx's Nanobody technologyplatform. This grant will allow us to continue to investigatealternative routes of administration for our therapeutic Nanobodieswhich could result in considerable benefits for patients. Advances inthis area could significantly impact on a number of our therapeuticprogrammes and open up more exciting new opportunities for Ablynx andits partners." -ends-About Ablynx [Euronext Brussels: ABLX] - http://www.ablynx.comFounded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceuticalcompany focused on the discovery and development of Nanobodies, anovel class of therapeutic proteins based on single-domain antibodyfragments, for a range of serious and life-threatening humandiseases. The Company currently has over 220 employees. Ablynxcompleted a successful IPO on Euronext Brussels [ABLX] on 7 November2007.For more information, please contact:College Hill Life Sciences - for International media enquiries:Sue Charles, Justine Lamond, Dr John McIntyret: +44 (0)20 7866 7857f: +44 (0)20 7866 7900e: ablynx(at)collegehill.comAblynx:Dr Edwin MosesChairman and CEOt: +32 (0)9 262 00 07m: +44 (0)7771 954 193 / +32 (0)473 39 50 68e: edwin.moses(at)ablynx.comEva-Lotta AllanChief Business Officert: +32 (0)9 262 00 75m: +32 (0)475 78 36 21 / +44 (0)7990 570 900e: eva-lotta.allan(at)ablynx.comhttp://hugin.info/137912/R/1356633/329674.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 23.11.2009 - 18:00 Uhr
Sprache: Deutsch
News-ID 8752
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 287 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX RECEIVES ?1.1 MILLION GRANT TO FURTHER DEVELOP NEW ROUTES OF
ADMINISTRATION FOR NANOBODIES®"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
